Summary

While progress has been made in predicting response to therapy for juvenile rheumatoid arthritis, major efforts are still needed in some areas before individualized treatment will be possible. This articles explores the current status of this topic for juvenile idiopathic arthritis, biomarker development, and cytokine blockade.